Skip to content Skip to footer
Subscribe Now
Insight+_Senior Editor
INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2020

The third quarter of 2020 was flooded with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisitions, Gilead acquired Immunomedics for ~$21B, Illumina acquired GRAIL for ~$8B, J&J acquired Momenta Pharmaceuticals for $6.5B and Nestlé acquired Aimmune Therapeutics for $2.6B, Sanofi acquired Principia Biopharma for ~$3.68B. Apart from…
October 29, 2020

Read more

Viewpoint_Adnrea_Stancati_2020
VIEWPOINTS

PharmaShots Interview: Takeda’s Andrea Stancati Shares Insights on Entyvio (vedolizumab) SC Formulation

In a recent interview with PharmaShots, Andrea Stancati, Vice President, Head GI Global Medical Franchise shares his insights and highlights of Entyvio (vedolizumab)Shots:The ongoing P-IIIb VISIBLE OLE study involves assessing of Entyvio (SC) in adult patients with UC or CD, following enrolment and participation in the VISIBLE 1 (UC) or VISIBLE 2 (CD)…
October 23, 2020

Read more

Announcements

PharmaShots Collaborates with DealForma to Deliver Deeper Biopharma Deal Insights 

Shots: PharmaShots is excited to announce a strategic collaboration with DealForma, bringing together two trusted insights platforms to unlock deeper, faster, and more actionable insights for the global biopharma community By combining PharmaShots’ expertly curated industry updates with DealForma’s comprehensive deal database, this collaboration delivers a powerful edge to researchers, analysts, investors, and biopharma leaders.Together, PharmaShots and DealForma…
October 20, 2020

Read more

Viewpoint_Kai_Te_Kaat_2020
VIEWPOINTS

PharmaShots Interview: QIAGEN’s Kai te Kaat Shares Insights on QIAprep& Viral RNA UM Kit

In a recent interview with PharmaShots, Kai te Kaat, the Vice President, Head of Franchise Oncology, MDx at QIAGEN shares his insights and highlights on QIAprep& Viral RNA UM Kit.Shots:QIAGEN to launch the QIAprep& Viral RNA UM Kit, designed to simplify and accelerate PCR swab analysis and remove key testing bottlenecks for Covid-19 and other RNA virusesThe…
October 19, 2020

Read more

Viewpoint_Lotus Mallbris_2020
VIEWPOINTS

PharmaShots Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insights on Baricitinib

In a recent interview with PharmaShots, Dr. Lotus Mallbris, the Vice President of Immunology Development at Eli Lilly shares her insights and highlights on Baricitinib.Shots:If approved, Baricitinib could be the first JAK inhibitor in the EU for adults with moderate to severe AD. EC's decision is expected in the next one-two months.Lilly is evaluating Baricitinib for SLE, for which…
October 12, 2020

Read more

Load more